If the original formulation of a drug worked for an application, then there is near a 100% probability that the reformulation will also work for the same application. As you point out this is not the same as the new formulation working in a totally different application.
The best way of thinking about all this is the AC part of CPACS is very likely, but the CP part has more risk. All the data we have collected suggests that CP has a very real chance of translating from animals to humans, but it is not certain. The good news is we will soon find out as the fully funded upcoming Phase 1a/b trial will provide an answer.
Even if CP doesn’t prove to work in humans, the AC opportunity doesn’t go away. There is still a huge need for different AC agents and RC220 provides this. The value of RC220 as a pure AC agent is yet to be reflected in the SP.
RAC Price at posting:
$1.61 Sentiment: Buy Disclosure: Held
(20min delay)